重组人血管内皮抑素腹腔内给药治疗恶性腹腔积液的实验研究  

Clinical research of endostatin in the treatment of malignant serous cavity effusion

作　　者：高文斌[1] 李花妮[1] 黄剑辉[1] 吕金燕[1] 王刚[1] 马建增[1] 郑真真[1] 邓蓉[1] 王若雨[1] 方今女[2] 

机构地区：[1]大连大学附属中山医院肿瘤内科,辽宁省116001 [2]延边大学医学部病理及病理生理学教研室

出　　处：《中华临床医师杂志（电子版）》2011年第13期3773-3776,共4页Chinese Journal of Clinicians(Electronic Edition)

基　　金：2010年度"CSCO-金港榄香烯肿瘤学研究生奖学助学基金"项目(J-2010-008)

摘　　要：目的初步探讨血管内皮抑素(ES)腹腔内给药治疗恶性腹腔积液的治疗机制。方法健康BABL/C小鼠,应用S180细胞建立腹腔积液模型。ES分为5.00mg/kg、2.50mg/kg及1.25mg/kg三组;阴性对照组为生理盐水组;阳性对照组为60.00mg/kg顺铂组。S180细胞腹腔注射接种5d后,实验药物隔日腹腔注射。记录小鼠体重作为腹水计量变化指标。计数小鼠存活只数计算存活率。结果 ES治疗癌性腹水的实验结果显示实验各组间小鼠体重具有统计学差异,高剂量组具有明显的优势,并且与顺铂对照组相当,组间比较具有统计学差异(P<0.05)。ES对恶性腹水小鼠存活率的影响提示,除低剂量组与中剂量组之间无统计学差异外,其余各组间均有统计学差异(P<0.05);不同时间存活率各组间比较均有统计学差异(P<0.01)。综合分析结果显示:在各实验组中,低剂量治疗组小鼠存活率显著高于其他各治疗组,低剂量组小鼠,存活时间长。结论重组人ES具有较好的抗肿瘤性腔内积液效果,并可延长腹水小鼠的生存时间,提高生存率。Objective A preliminary discussion of endostatin abdominal cavity chemotherapy in the treatment of malignant serous cavity effusion.Methods Endostatin,cisplatin and saline of different dosages were injected into the abdominal carity of mice with ascites,then conduct a comparison.Endostatin of 5.00 mg/kg,2.50 mg/kg and 1.25 mg/kg was injected into three groups,saline into negative control group,positive cisplatin(60.00 mg/kg) into positive control group,kept a record of the mice weight as a measurement indicator for ascites,and worked out the mice survival rate by counting the number of mice alive.Results Experiment showed that there were significant differences in the weight among these various groups of mice.A distinctive advantage(P<0.05)in the high-dosage group was existed,nearly equivalent to the cisplatin comparison group.Endostatin had effects on the survival rate of the mice with malicious ascites.There were no obvious statistical differences between the low-dosage group and medium-dosage group,but differences do existed in the other groups(P<0.05),and survival rate at different times was statistically quite different(P<0.01).A high survival rate and long life span were seen in the low-dosage group.Conclusions Recombinant human endostatin can work well on controlling malignant serous cavity effusion to prolong mice life span and raise survival rate.

关 键 词：注射 腹腔内 肿瘤 血管内皮抑素 

分 类 号：R730.5[医药卫生—肿瘤]